SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-22-063325
Filing Date
2022-10-11
Accepted
2022-10-11 17:20:52
Documents
51
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea166878-6k_nlspharma.htm   iXBRL 6-K 49977
2 CONDENSED FINANCIAL STATEMENTS (UNAUDITED) OF NLS PHARMACEUTICS AS OF AND FOR TH ea166878ex99-1_nlspharma.htm   iXBRL EX-99.1 262831
3 MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERA ea166878ex99-2_nlspharma.htm EX-99.2 168816
  Complete submission text file 0001213900-22-063325.txt   2666713

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE nlsp-20220630.xsd EX-101.SCH 38722
5 XBRL CALCULATION FILE nlsp-20220630_cal.xml EX-101.CAL 30477
6 XBRL DEFINITION FILE nlsp-20220630_def.xml EX-101.DEF 135137
7 XBRL LABEL FILE nlsp-20220630_lab.xml EX-101.LAB 294462
8 XBRL PRESENTATION FILE nlsp-20220630_pre.xml EX-101.PRE 147129
45 EXTRACTED XBRL INSTANCE DOCUMENT ea166878-6k_nlspharma_htm.xml XML 196496
Mailing Address THE CIRCLE 6 8058 ZURICH V8 CH-6370
Business Address THE CIRCLE 6 8058 ZURICH V8 CH-6370 41-41-618-80-00
NLS Pharmaceutics Ltd. (Filer) CIK: 0001783036 (see all company filings)

IRS No.: 000000000 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-39957 | Film No.: 221304816
SIC: 2834 Pharmaceutical Preparations